Literature DB >> 11303816

Invasive Group C Streptococcus infection associated with rhabdomyolysis and disseminated intravascular coagulation in a previously healthy adult.

I C Ojukwu1, D W Newton, A E Luque, M Y Kotb, M Menegus.   

Abstract

Infections with Group C Streptococci can lead to severe disease, particularly in individuals with underlying illnesses such as cardiovascular disease, malignancy or immunosuppression. We report the first case of rhabdomyolysis and disseminated intravascular coagulation secondary to Group C Streptococcus in a previous healthy male. A toxic shock-like syndrome associated with Group C and Group G Streptococci has been reported. However, unlike with Group A Streptococci, production of endotoxins by these organisms is less well defined. We tested the patient's isolate for its ability to produce superantigenic toxins and to induce a mitogenic response. Although it is not known whether Group C Streptococci require special growth conditions for the production of superantigens, we could not demonstrate either the production of exotoxins or the induction of a mitogenic response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303816     DOI: 10.1080/00365540151060969

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  Cloning, expression, and characterization of the superantigen streptococcal pyrogenic exotoxin G from Streptococcus dysgalactiae.

Authors:  Jizi Zhao; Tomohito Hayashi; Susanna Saarinen; Anastassios C Papageorgiou; Hidehito Kato; Ken'ichi Imanishi; Teruo Kirikae; Ryo Abe; Takehiko Uchiyama; Tohru Miyoshi-Akiyama
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

2.  Characterization of group C and G streptococcal strains that cause streptococcal toxic shock syndrome.

Authors:  Shinnosuke Hashikawa; Yoshitsugu Iinuma; Manabu Furushita; Teruko Ohkura; Toshi Nada; Keizo Torii; Tadao Hasegawa; Michio Ohta
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

Review 3.  Fatal case of toxic shock-like syndrome due to group C streptococcus associated with superantigen exotoxin.

Authors:  Tony M Korman; Anthony Boers; Travis M Gooding; Nigel Curtis; Kumar Visvanathan
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

4.  Refractory Toxic Shock-Like Syndrome from Streptococcus dysgalactiae ssp. equisimilis and Intravenous Immunoglobulin as Salvage Therapy: A Case Series.

Authors:  Marjan Islam; Dennis Karter; Jerry Altshuler; Diana Altshuler; David Schwartz; Gianluca Torregrossa
Journal:  Case Rep Infect Dis       Date:  2016-08-15

5.  Therapeutic Effects of Procainamide on Endotoxin-Induced Rhabdomyolysis in Rats.

Authors:  Chih-Chin Shih; Hiong-Ping Hii; Cheng-Ming Tsao; Shiu-Jen Chen; Shuk-Man Ka; Mei-Hui Liao; Chin-Chen Wu
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

6.  Rhabdomyolysis with different etiologies in childhood.

Authors:  Demet Alaygut; Meral Torun Bayram; Belde Kasap; Alper Soylu; Mehmet Türkmen; Salih Kavukcu
Journal:  World J Clin Pediatr       Date:  2017-11-08

7.  Group C streptococcal cellulitis, looking deeper than the skin.

Authors:  Hasan Khosravi; Amy Hou; Robert C Colgrove; Irmgard Behlau
Journal:  JAAD Case Rep       Date:  2018-09-18

8.  Rhabdomyolysis in community acquired bacterial sepsis--a retrospective cohort study.

Authors:  Anita A Kumar; Emmanuel Bhaskar; Ghanshyam Palamaner Subash Shantha; Porchelvan Swaminathan; Georgi Abraham
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

9.  Rhabdomyolysis after group C streptococcal infection.

Authors:  Hilde Haugedal Nordal; Bård Reiakvam Kittang; Laurence A Bindoff
Journal:  Infect Dis Rep       Date:  2010-10-01

10.  Immunohistochemical detection of Lp25 and LipL32 proteins in skeletal and cardiac muscles of fatal human leptospirosis.

Authors:  Silvia D'Andretta Iglezias; Patrícia Antonia Estima Abreu; Cristina Kanamura; Antonio José Magaldi; Antonio Carlos Seguro; Thales De Brito
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-11-09       Impact factor: 1.846

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.